Johnson & Johnson's Liquidity Slides to 70th as Regulatory and Supply Chain Pressures Dampen Investor Confidence

. 9, , , . The decline follows recent regulatory scrutiny over product safety concerns and supply chain disruptions in its pharmaceutical division, which has dampened investor confidence. A pending FDA review of a key drug candidate is expected to add short-term volatility to the stock.

Analysts noted that the company’s recent earnings report highlighted margin compression in its consumer health segment, . , mixed guidance on R&D expenditures has raised questions about long-term profitability. .

To build an accurate back-test I need to nail down a few practical details about how you want the strategy implemented: Universe, ranking/selection timing, trade execution prices, position sizing, and costs & constraints. With those parameters confirmed I can generate the daily signals, , .